Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase NA 1Phase 2/3 1

Status

Recruiting 6Active not recruiting 5Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 4Observational 2

Sponsor

Cancer Type

Breast 6

Conditions

Breast Neoplasms 552Neoplasms 502Carcinoma, Non-Small-Cell Lung 419Prostatic Neoplasms 326Colorectal Neoplasms 310Lung Neoplasms 280Neoplasm Metastasis 233Leukemia, Myeloid, Acute 222Ovarian Neoplasms 205Pancreatic Neoplasms 195Multiple Myeloma 186Recurrence 141Squamous Cell Carcinoma of Head and Neck 140Brain Neoplasms 139Stomach Neoplasms 138Melanoma 132Carcinoma, Hepatocellular 130Endometrial Neoplasms 127Glioblastoma 124Triple Negative Breast Neoplasms 116Precursor Cell Lymphoblastic Leukemia-Lymphoma 115Hematologic Neoplasms 102Head and Neck Neoplasms 100Urinary Bladder Neoplasms 98Carcinoma, Renal Cell 98Lymphoma 97Glioma 94Sarcoma 93Esophageal Neoplasms 90Uterine Cervical Neoplasms 88

Interventions

Trastuzumab 3pertuzumab 2Docetaxel 2tucatinib 1Neoadjuvant Therapy 1Injections 1Genetic Testing 1Carboplatin 1Capecitabine 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × HER2-positive Breast Cancer × 90 days × Clear all
NCT04638725 2026-06-04

SIGHER

Centre Paul Strauss

Recruiting
9,000 enrolled
Breast

HER2-positive Breast Cancer

NCT07518173 2026-06-04

A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3 Recruiting
596 enrolled
Breast

HER2-positive Breast Cancer

NCT07616440 2026-06-04

Pilot Study on the Clinical Efficacy of Focused Ultrasound-Mediated Targeted Drug Delivery System Combined With Neoadjuvant Therapy for HER2-Positive Breast Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase NA Recruiting
20 enrolled
Breast

HER2-positive Breast Cancer

NCT07413939 2026-05-11

BREnnA

Hoffmann-La Roche

Phase 2/3 Recruiting
650 enrolled
Breast

HER2-positive Breast Cancer

NCT06518382 2026-04-15

Tumor-microenvironment Spatial Interaction to Identify Markers of Resistance to Therapy in HER2+ Breast Cancer Patients

IRCCS Ospedale San Raffaele

Recruiting
10 enrolled
Breast

HER2-positive Breast Cancer

NCT07043725 2026-03-27

A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Recruiting
544 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡